Since lupus can cause problems anywhere in the body, your child may need to see different types of pediatricians (doctors who provide care to children from birth to young adulthood) and health care ...

Pediatric lupus grants under the Michael Jon Barlin Pediatric Lupus Research program provide funding for research projects that have the potential to significantly advance the field of or impact the ...

The U.S. Food and Drug Administration has given Seattle Children’s the green light to conduct a clinical trial for a drug that researchers hope can help fight pediatric lupus. The drug known as ...

The US Food and Drug Administration (FDA) has approved Benlysta (belimumab) autoinjector for patients aged 5 years or older with active systemic lupus erythematosus (SLE) on standard therapy. This is ...

In a cross-sectional study, insulin growth factor binding protein 2 (IFGBP-2) showed promise as a prognosis biomarker for renal disease in pediatric lupus nephritis (LN). Serum insulin growth factor ...

Treat-to-target has long been used in adults, but a new study finds it is warranted in pediatric cases, too. A new study suggests the treat-to-target (T2T) strategy, long in use to treat adult ...

Systemic lupus erythematosus (SLE) is a multifactorial autoimmune rheumatic disease. Although its highest prevalence is among women of childbearing age, the disease is not confined within this ...

MMF induction is a viable alternative to cyclophosphamide for treating mixed proliferative lupus nephritis in children. Oral mycophenolate mofetil (MMF) is as effective as intravenous cyclophosphamide ...

Please provide your email address to receive an email when new articles are posted on . Patients with pediatric discoid lupus erythematosus combined with systemic lupus erythematosus were most likely ...

Lupus can develop in people of all ages, including children. Lupus that develops under the age of 18 (pediatric lupus) tends to be more severe than lupus that starts in adulthood. Lupus is an ...

The FDA has expanded the approval of belimumab to include pediatric patients 5 to 17 years of age with active lupus nephritis. The Food and Drug Administration (FDA) has expanded the approval of ...

Please provide your email address to receive an email when new articles are posted on . Black children and those of more than one racial background were less likely to achieve LLDAS and had higher ...